Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy

被引:0
|
作者
Barbara Conner-Spady
Ceinwen Cumming
Jean-Marc Nabholtz
Philip Jacobs
Douglas Stewart
机构
[1] University of Alberta,
[2] Cross Cancer Institute,undefined
[3] University of California Los Angeles (UCLA),undefined
[4] Tom Baker Cancer Centre,undefined
来源
Quality of Life Research | 2001年 / 10卷
关键词
Breast cancer; EuroQol; Health-related quality of life; Health status; Responsiveness;
D O I
暂无
中图分类号
学科分类号
摘要
Objective: To assess the responsiveness of the EuroQol (EQ-5D) by comparing it with the Functional Living Index-Cancer (FLIC) and a self-reported rating of health-related quality of life (HRQL). Methods: HRQL was measured four times during the course of high dose chemotherapy (HDC) and bone marrow transplantation in 40 patients with stage II and III breast cancer. Measurements were at baseline (T1), pre-HDC (T2), 3 weeks post-HDC (T3), and 3 months post-HDC (T4). Results: Effect size ranged from 1.16 (T1–T3) to 0.66 (T3–T4) for the EQ-5D and 0.85–0.91 respectively for the FLIC. No significant differences in effect sizes between the EQ-5D and the FLIC were found. Repeated measures ANOVA yielded a significant change for all measures, with HRQL decreasing post-HDC and returning to baseline levels by 3 m post-HDC. EQ-5D dimensions changed significantly over time for mobility, self-care, and usual activities. EQ-5D index scores at T3 had a bimodal distribution. Interpretation of psychological changes was facilitated by an analysis of FLIC items. Conclusions: The EQ-5D is responsive to the clinically large changes associated with HDC in breast cancer patients. The bimodal distribution of the EQ-5D index has implications for the interpretation of EQ-5D change scores.
引用
收藏
页码:479 / 486
页数:7
相关论文
共 50 条
  • [1] Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy
    Conner-Spady, B
    Cumming, C
    Nabholtz, JM
    Jacobs, P
    Stewart, D
    QUALITY OF LIFE RESEARCH, 2001, 10 (06) : 479 - 486
  • [2] Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors
    BE Brockstein
    C Smiley
    J Al-Sadir
    SF Williams
    Bone Marrow Transplantation, 2000, 25 : 885 - 894
  • [3] Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors
    Brockstein, BE
    Smiley, C
    Al-Sadir, J
    Williams, SF
    BONE MARROW TRANSPLANTATION, 2000, 25 (08) : 885 - 894
  • [4] High-Dose Chemotherapy in Breast Cancer
    Diana E. Lake
    Clifford A. Hudis
    Drugs, 2004, 64 : 1851 - 1861
  • [5] High-dose chemotherapy (CTM) for breast cancer
    Damon, LE
    Wolf, JL
    Rugo, HS
    Gold, E
    Zander, AR
    Cassidy, M
    Cecchi, G
    Cohen, N
    Irwin, D
    Tracy, M
    Ries, CA
    Linker, CA
    BONE MARROW TRANSPLANTATION, 2000, 26 (03) : 257 - 268
  • [6] High-dose chemotherapy in advanced breast cancer
    Viens, P
    Maraninchi, D
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 41 (02) : 141 - 149
  • [7] Randomized trials of high dose chemotherapy for breast cancer
    Antman, KH
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1471 (03): : M89 - M98
  • [8] Whither high-dose chemotherapy in breast cancer?
    Mayer, A
    Earl, H
    BREAST CANCER RESEARCH, 2001, 3 (01) : 8 - 10
  • [9] High-dose chemotherapy (CTM) for breast cancer
    LE Damon
    JL Wolf
    HS Rugo
    E Gold
    AR Zander
    M Cassidy
    G Cecchi
    N Cohen
    D Irwin
    M Tracy
    CA Ries
    CA Linker
    Bone Marrow Transplantation, 2000, 26 : 257 - 268
  • [10] Whither high-dose chemotherapy in breast cancer?
    Astrid Mayer
    Helena Earl
    Breast Cancer Research, 3